GlaxoSmithKline (GSK) has announced $100 million of new investment in its manufacturing site in Hamilton, Montana to expand the production capacity of key components of the adjuvant system used in several of its vaccines, including Shingrix, a shingles vaccine, which was approved by the US Food and Drug Administration in October 2017.

The Hamilton vaccines facility manufactures components of GSK’s adjuvant technologies, which this investment will expand further.

Over the next few years, the Hamilton site expansion is expected to add a combination of temporary construction and contracting jobs as well as new permanent positions, including scientists, engineers, and manufacturing and quality professionals.

Hamilton is one of nine GSK manufacturing sites in the US and 86 sites globally, which produce a variety of prescription medicines, vaccines and consumer healthcare products.

Source: GlaxoSmithKline